Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Angelalign TechnologyFRA:77D -6.49%75 ROC (Joel Greenblatt) % is 32.05% as of Dec. 2025, which is 60% below its 10-year median of 79.39. GuruFocus rates FRA:77D with a GF Score™ of 75/100 and a GF Value™ of €11.19 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 838 Medical Devices & Instruments companies, Angelalign Technology ranks better than 81.62% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Angelalign Technology's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 32.05%.
The historical rank and industry rank for Angelalign Technology's ROC (Joel Greenblatt) % or its related term are showing as below:
FRA:77D'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 14.19 Med: 79.39 Max: 173.71
Current: 33.9
During the past 8 years, Angelalign Technology's highest ROC (Joel Greenblatt) % was 173.71%. The lowest was 14.19%. And the median was 79.39%.
FRA:77D's ROC (Joel Greenblatt) % is ranked better than 81.62% of 838
companies
in the Medical Devices & Instruments industry
Industry Median: 4.145
vs FRA:77D: 33.90
Angelalign Technology's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was -37.50% per year.
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Angelalign Technology ROC (Joel Greenblatt) % Related Terms
Angelalign Technology ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Angelalign Technology's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:77D vs ISRG, BDX, MDLN: ROC (Joel Greenblatt) % Comparison
For the Medical Instruments & Supplies subindustry, Angelalign Technology's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Angelalign Technology ROC (Joel Greenblatt) % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Angelalign Technology's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Angelalign Technology's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 32.05% mean?
Angelalign Technology (FRA:77D) has a ROC (Joel Greenblatt) % of 32.05% as of Dec. 2025. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Angelalign Technology and its competitors. This is 60% below median its historical median of 79.39. Over the past decade, Angelalign Technology's ROC (Joel Greenblatt) % has ranged from 14.19 to 173.71. According to the industry distribution chart, Angelalign Technology ranks #154 out of 838 companies in the Medical Devices & Instruments industry, placing it in the top 18.4%.
Is Angelalign Technology's ROC (Joel Greenblatt) % too high?
Angelalign Technology's current ROC (Joel Greenblatt) % of 32.05% is 60% below median its 10-year median of 79.39. Over the past 10 years, this metric has ranged from a low of 14.19 to a high of 173.71. The Medical Devices & Instruments industry median ROC (Joel Greenblatt) % is 4.15. Angelalign Technology's value of 32.05% is 673.2% above this industry median. Based on the distribution chart, Angelalign Technology ranks #154 out of 838 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Angelalign Technology has a GF Score™ of 75/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Angelalign Technology's ROC (Joel Greenblatt) % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Angelalign Technology ranks #154 out of 838 companies for ROC (Joel Greenblatt) %. This places Angelalign Technology in the top 18% of its industry — outperforming the majority of peers. The industry median ROC (Joel Greenblatt) % is 4.15. Angelalign Technology's value of 32.05% is 673.2% above this benchmark. Historically, Angelalign Technology's own ROC (Joel Greenblatt) % has ranged from 14.19 to 173.71 over the past decade. While the company's 10-year median is 79.39 vs. the industry median of 4.15, Angelalign Technology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Medical Devices & Instruments company?
The median ROC (Joel Greenblatt) % among Medical Devices & Instruments companies is 4.15, based on 838 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Angelalign Technology's current ROC (Joel Greenblatt) % of 32.05% is 673.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Angelalign Technology and its competitors. For the Medical Devices & Instruments industry, the median ROC (Joel Greenblatt) % is 4.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Angelalign Technology's current ROC (Joel Greenblatt) % is 32.05%, which is 60% below median its own 10-year median of 79.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Angelalign Technology stock overvalued right now?
Based on GuruFocus' analysis, Angelalign Technology (FRA:77D) is currently considered Significantly Undervalued. The stock's GF Value™ is €11.19, compared to a current price of €8.65 — trading 22.7% below its estimated fair value. The current ROC (Joel Greenblatt) % is 32.05%, which is 60% below median its 10-year median of 79.39 and 673.2% above the Medical Devices & Instruments industry median of 4.15. Angelalign Technology's overall GF Score™ is 75/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Angelalign Technology (FRA:77D), the current ROC (Joel Greenblatt) % is 32.05% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Angelalign Technology (FRA:77D) Overvalued in 2026?
Based on GuruFocus' analysis, Angelalign Technology stock appears to be undervalued.
The current stock price of €8.65 is trading 22.7% below its estimated GF Value™ of €11.19.
GuruFocus considers Angelalign Technology to be Significantly Undervalued.
Key valuation signals for FRA:77D:
ROC (Joel Greenblatt) %: 32.05% (60% below median its 10-year median of 79.39)
GF Value™: €11.19 vs. price of €8.65 (22.7% below fair value)
Industry Position: 673.2% above the Medical Devices & Instruments median (#154 of 838)
No single metric tells the full story. See the FRA:77D stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Angelalign Technology Inc is an investment holding company. It is principally engaged in clear aligner treatment solutions, including treatment planning services, manufacturing, and marketing of clear aligners. The company provides dental professionals with self-developed digital orthodontic solutions. The company's Angelalign clear aligner system facilitates dental professionals throughout the entire clear aligner treatment process, including digitally-assisted case assessment support and treatment planning services, provide dental professionals with digitally-assisted case assessment support and treatment planning services, and helps dental professionals design, review, and modify treatment plans.
75GF Score
Get the complete analysis for FRA:77D
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:77D has been successfully added to your 
